FDAnews
www.fdanews.com/articles/81772-memory-announces-collaboration-to-develop-pde10-inhibitors-for-central-nervous-system-disorders-with-amgen

MEMORY ANNOUNCES COLLABORATION TO DEVELOP PDE10 INHIBITORS FOR CENTRAL NERVOUS SYSTEM DISORDERS WITH AMGEN

October 19, 2005

Memory Pharmaceuticals Corp. (NASDAQ:MEMY) today announced that it has entered into an exclusive worldwide collaboration and license agreement with Amgen to develop PDE10 inhibitors as human therapeutics, including as a potential treatment for certain neurological and psychiatric disorders. The collaboration will focus on the optimization of lead compounds that the Company has identified and that have demonstrated effectiveness in the selective inhibition of PDE10 activity in several animal models.

Biotech Intelligence (http://www.biotech-intelligence.com/html/html/8b4c6454ce7c194be59f791296e220da.html)